Janssen/J&J Invokana wins US SGLT2 race; 5 postmarket studies required
This article was originally published in Scrip
Executive Summary
With the FDA's nod on 29 March for Invokana (canagliflozin), Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, triumphed in the race to have the first selective sodium glucose co-transporter 2 (SGLT2) inhibitor approved for the US market to treat adults with Type II diabetes – beating other competitors Boehringer Ingelheim's and Lilly's empagliflozin and AstraZeneca's and Bristol-Myers Squibb's dapagliflozin.